Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin and complex rehabilitation for chronic fatigue in post-COVID syndrome
2024-516174-30-01Phase 2Completed
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pregabalin in myalgic encephalomyelitis (ME) (2 arms), sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation. Primary endpoints: Change in fatigue intensity (MFI-20) and Change in walking distance (6 Minute Walking Test). Started Oct 2024; status: completed.
02
Drugs
pregabalin
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2024-516174-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516174-30-01.